等待開盤 09-20 09:30:00 美东时间
+0.140
+0.29%
GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today...
06-25 04:05
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisitio...
02-22 20:50
-- AYVAKIT® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval -- -- Expanding mast cell disease l...
01-08 21:00
KANSAS CITY, Mo., Sept. 28, 2023 /PRNewswire/ -- Avantis Investors®, a $27 billion* investment offering from global asset manager American Century Investments®, further expands its investmen...
2023-09-28 21:32
KANSAS CITY, Mo., June 29, 2023 /PRNewswire/ -- Today, Avantis Investors®, a $25 billion* investment offering from global asset manager American Century Investments®, expands its exchange tr...
2023-06-29 22:00